We set out to identify predictors for the prophylactic effect of placebo injections in subjects with migraine by post hoc analysis of 81 subjects with episodic migraine receiving single-blind placebo injections in a prospective trial of botulinum toxin. Possible predictors of placebo prophylaxis were compared among placebo responders (PRs) and placebo non-responders (PNRs). There were 34 PRs (42%) and 47 PNRs (58%). Male gender [odds ratio (OR) 5.83, 95% confidence interval (CI) 1.12, 30.14, P = 0.022], a history of opioid use (OR 4.44, 95% CI 1.47, 13.41, P = 0.005) and injections in the neck/shoulders (OR 2.44, 95% CI 0.93, 3.19, P = 0.033) were associated with placebo response. Of subjects with two or more of these signs, 88% were PRs compared with 31% of subjects with one or less. Male gender, opioid use and injections in the neck/shoulders are associated with placebo prophylaxis. These findings may have important implications for the design of future clinical trials and for the clinical management of migraineurs. © Blackwell Publishing Ltd 2007.
CITATION STYLE
Schwedt, T. J., Hentz, J. G., & Dodick, D. W. (2007). Factors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum toxin for migraine. Cephalalgia, 27(6), 528–534. https://doi.org/10.1111/j.1468-2982.2007.01332.x
Mendeley helps you to discover research relevant for your work.